|1.||Prestwich, Glenn D: 4 articles (01/2013 - 07/2009)|
|2.||Xu, Xiaoyu: 3 articles (04/2010 - 07/2009)|
|3.||Zhang, Honglu: 2 articles (09/2009 - 07/2009)|
|4.||Wu, Sherry: 1 article (12/2015)|
|5.||Exley, Mark: 1 article (12/2015)|
|6.||Lange, Martin: 1 article (12/2015)|
|7.||Usheva, Anny: 1 article (12/2015)|
|8.||Nowak-Machen, Martina: 1 article (12/2015)|
|9.||Robson, Simon C: 1 article (12/2015)|
|10.||Sevastou, Ioanna: 1 article (01/2013)|
04/01/2010 - "Finally, tumor vascularization was dramatically reduced in the A549 tumors treated with BrP-LPA. "
07/01/2009 - "Moreover, both the anti- and syn-BrP-LPA significantly reduced tumors at 3 mg/kg."
09/01/2009 - "Specifically, we created several three-dimensional (3D) human tumor xenografts and evaluated the tumor response to BrP-LPA, a novel dual function LPA antagonist/ATX inhibitor (LPAa/ATXi). "
01/01/2011 - "The biological significance of this regulation mechanism was revealed by demonstrating that TSA-induced ATX protected cancer cells against TSA-induced apoptosis by producing LPA through its lysoPLD activity, which could be reversed by BrP-LPA and S32826, the inhibitors of the ATX-LPA axis. "
04/01/2010 - "Third, tumor volumes increased rapidly in both Matrigel and Extracel-HP encapsulated A549 cells, and tumor growth was markedly inhibited by BrP-LPA treatment. "
01/01/2011 - "In co-culture experiments using bEND.3 and mouse GL-261 glioma cells, treatment with BrP-LPA reduced Akt phosphorylation in both irradiated cell lines and decreased survival and migration of irradiated GL-261 cells. "
01/01/2011 - "Using heterotopic tumor models of GL-261, mice treated with BrP-LPA and irradiation showed a tumor growth delay of 6.8 days compared to mice treated with irradiation alone indicating that inhibition of ATX and LPA receptors may significantly improve malignant glioma response to radiation therapy. "
01/01/2013 - "Here we show that administration of 1-bromo-3(S)-hydroxy-4-(palmitoyloxy)butyl-phosphonate (BrP-LPA), a metabolically stabilized analog of LPA and a dual function inhibitor of ATX and pan-antagonist of LPA receptors, attenuates collagen induced arthritis (CIA) development, thus validating the ATX/LPA axis as a novel therapeutic target in RA. "
|1.||Lysophosphatidic Acid Receptors
|6.||lysophosphatidic acid (MOPA)
|1.||Heterologous Transplantation (Xenotransplantation)